UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4574-4580

2011

Volltextzugriff (PDF)

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Volltextzugriff (PDF)

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Volltextzugriff (PDF)

Inhibiting the Aurora B Kinase Potently Suppresses Repopulation During Fractionated Irradiation of Human Lung Cancer Cell Lines

International journal of radiation oncology, biology, physics, 2012-10, Vol.84 (2), p.492-499

2012

Volltextzugriff (PDF)

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Investigational new drugs, 2014-02, Vol.32 (1), p.123-134

2014

Volltextzugriff (PDF)

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Lung cancer (Amsterdam, Netherlands), 2012-07, Vol.77 (1), p.183-191

2012

Volltextzugriff (PDF)

Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3076-3082

2013

Volltextzugriff (PDF)

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Commentary

The Journal of thoracic and cardiovascular surgery, 2010, Vol.139 (6), p.1424-1430

2010

Volltextzugriff (PDF)

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As FirstLine Treatment for Advanced Non―Small-Cell Lung Cancer

Journal of clinical oncology, 2011, Vol.29 (19), p.2667-2674

2011

Volltextzugriff (PDF)

The role of surgery in stage IIIA non-small cell lung cancer: Multidisciplinary approach to lung cancer

Hematology/oncology clinics of North America, 2005, Vol.19 (2), p.vi-vii

2005

Volltextzugriff (PDF)

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

The Lancet (British edition), 2009-05, Vol.373 (9674), p.1525-1531

2009

Volltextzugriff (PDF)

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Annals of oncology, 2014-08, Vol.25 (8), p.1462-1474

2014

Volltextzugriff (PDF)

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Annals of oncology, 2014-08, Vol.25 (8), p.1475-1484

2014

Volltextzugriff (PDF)

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Annals of oncology, 2014-09, Vol.25 (9), p.1681-1690

2014

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Annals of oncology, 2011-07, Vol.22 (7), p.1507-1519

2011

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4794-4805

2012

Volltextzugriff (PDF)

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

Lung cancer (Amsterdam, Netherlands), 2013-10, Vol.82 (1), p.83-89

2013

Volltextzugriff (PDF)

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.91-96

2005

Volltextzugriff (PDF)

Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 1998, Vol.42 (2), p.99-104

1998

Volltextzugriff (PDF)

Contributions of the Conference Interdisciplinary Treatment of Lung Cancer, Münster, Germany, March 2-3, 2001

Lung cancer, 2001, Vol.33

2001

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(19)
Tagungsberichte
(1)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(20)
Humans
(16)
Life Sciences & Biomedicine
(16)
Pneumology
(16)
Science & Technology
(16)
Tumors Of The Respiratory System And Mediastinum
(16)
Oncology
(14)
Tumors
(12)
Female
(11)
Male
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Neoplasms - Drug Therapy
(10)
Middle Aged
(10)
Aged
(9)
Antineoplastic Agents
(9)
Lung Neoplasms - Pathology
(9)
Pharmacology. Drug Treatments
(9)
Adult
(8)
Carcinoma, Non-Small-Cell Lung - Pathology
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Inhibiting the Aurora B Kinase Potently Suppresses Repopulation During Fractionated Irradiation of Human Lung Cancer Cell Lines

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Commentary

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As FirstLine Treatment for Advanced Non―Small-Cell Lung Cancer

The role of surgery in stage IIIA non-small cell lung cancer: Multidisciplinary approach to lung cancer

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

Contributions of the Conference Interdisciplinary Treatment of Lung Cancer, Münster, Germany, March 2-3, 2001

Aktive Filter

Suchergebnisse filtern